Volume 32 Issue 1 - January 3, 2020 PDF
To Investigate the Effects of 3'UTR Usage Switch and Its Regulator on Causing Resistance of Second-Generation Anti-Androgen Drug in Prostate Cancer
The Institute of Basic Medical Sciences, College of Medicine
Font Enlarge
Prof. Shih-Chieh Lin established his lab at The Institute of Basic Medical Sciences since February 2018. His expertise is cancer biology, bioinformatics, translational medicine endocrinology, and reproductive physiology. Now, his current work mainly focuses on study of prostate cancer.
Taiwan has already become an aging society. Prostate cancer is the most common malignancy among elderly men. Metastatic castration-resistant prostate cancer (mCRPC) is a more malignant and lethal type of prostate cancer. Recently, several second-generation anti-androgen drugs are approved by US FDA providing alternative therapies and hopes for treatment of mCRPC patients. However, several critical and emergent issues such as drug selection, treatment sequential order, and drug resistance, are raised subsequently. Especially, National Health Insurance in Taiwan only covers the cost for one kind of those expensive drugs at the initial treatment. Since there is no available drug selection guideline and lack of alternative therapy once resistance to second-generation anti-androgen drugs has developed, it prompts us to investigate the underlying mechanism causing resistance of second-generation anti-androgen drug with a goal to develop novel therapy for mCRPC patients with resistance for second-generation anti-androgen drug. In addition, we also aim to identify biomarkers of drug response to predict resistance for different drugs. Although some reports have investigated the mechanisms of drug resistance for second-generation anti-androgen drugs recently, most of them are still focused on dysregulation of AR and androgen. Herein, we have proposed for the first time that a novel underlying mechanism causing resistance of second-generation anti-androgen drug by analyzing NGS results from enzalutamide-sensitive and -resistant mCRPC clinical specimens. Furthermore, a crucial regulator mediated this novel mechanism and its potential drug have been identified and studied by our research team. Hopefully, results from this grant proposal will have tremendous impacts on academic research, treatment efficacy of mCRPC patients, drug usage selection for clinical doctors, and valuable information for developing policy for the National Health Insurance Program.
There is no miracle for scientific work and accumulation of experience is the only way leading to the success! I am very grateful to receive MOST grant support for my research project. Therefore, our study will have a chance to become leading research in the world. Furthermore, I deeply appreciate all the comments from grant reviewers because their valuable opinions make our research project become better. Most importantly, I also appreciate National Cheng Kung University (NCKU) to provide the excellent research environment for me to perform interesting research based on my expertise. Hopefully, I can train a group of outstanding young researchers for our country in the future. I will try my best to elevate the international visibility of NCKU and Taiwan via our research.
< Previous
Next >
Copyright National Cheng Kung University